USE OF 20(R)-22-OXA-VITAMIN D ANALOGUES FOR THE TREATMENT OF SKIN AGEING

Abstract: The present invention relates to the use of 20(R)-22-oxavitamin D analogues for treatment or prevention of skin ageing, and to the use of such compounds for preparation of pharmaceutical compositions for treatment and/or prevention of skin ageing.

Description: Use of 20(R)-22-oxa-Vitamin D analogues for the treatment of skin ageing This invention relates to the use of 20(R)-22-oxa- vitamin D analogues for treatment or prevention of skin ageing, and to the use of such compounds for preparation of pharmaceutical compositions for treatment and/or prevention of skin ageing. Ageing of the skin involves the intrinsic process of senescense and extrinsic damage induced by chronic exposure to UV radiation (photoageing) . Clinically, the ageing process is characterized by skin changes such as thinning, loss of elasticity and wrinkling. The main histologic features of aged skin in¬ clude epidermal athrophy and dysplasia as well as dermal damage with marked elastosis and loss of collagen. It has recently been demonstrated that topical tretinoin can improve the features of photodamaged skin by daily continuous application (1). However, because of the irritant properties of tretinoin the use of this drug is associated with unpleasant side effects, and therefore there is a need for better tolerated and more active prod¬ ucts for prevention and reversal of skin ageing. We have now found that certain analogues of vitamin D are active in the prevention and treatment of skin ageing and at the same time are free of the irritant effects cha¬ racteristic of retinoids. It is well known that a number of vitamin D metabo¬ lites and analogues inhibit the proliferation of keratino- (1) Weiss, J.S. et al, JAMA, 259 (1988), 527-32. cytes (2) (3)(4). As a result of this, a thinning of " the epidermal layer is seen in guinea pigs in areas treated with a petrolatum ointment containing such an analogue com¬ pared to areas treated with petrolatum alone (4). A similar reduction of epidermal thickness is seen in psoriatic le¬ sions treated with 1,25-dihydroxyvitamin D_ (3). However, in contrast to this, we have now surpris¬ ingly seen a profound thickening of epidermis in rats treated with an ointment containing a member of a series of new 20(R)-22-oxa-vitamin D analogues e.g. those described in our copending international application PCT/DK90/00036, indicating the usefulness of such preparations for treat¬ ment or profylaxis of skin ageing, including photo-ageing. The compounds described in PCT/DK90/00036 are repre- sented by the general formula I in which formula R stands for an alkyl group containing from 4 to 12 carbon atoms optionally substituted with a hydroxy group. (2) Kuroki, T. et al, Ann. N.Y. Acad. Sci. (1988) 548, 45-55. (3) Holick, M.F., Proc. Exp. Biol. Med., 191 (1989), 246 (4) Kato, T. et al, Br. J. Dermatol., 117 (1987), 528-30 Preferably R is a group of formula II where n is an integer from 1 to 7; R 1 and R2, which may be the same or different, stand for hydrogen, lower alkyl, lower cycloalkyl, or, taken together with the carbon atom (starred in formula II) bearing the group X, R 1 and R2 can form a C~-C R carbocyclic ring; X stands for hydrogen or hydroxy. In the context of this invention, the expression "lower alkyl" indicates a straight or branched saturated or unsaturated carbon chain containing from 1 to 5 carbon atoms, and the expression "lower cyclo-alkyl" indicates a saturated or unsaturated C 3 ~C 7 carbocyclic ring. As can be seen from formula I and II, depending on the meanings of R, X, R 1 and R2, the compounds of the in- vention can comprise several diastereoisomeric forms (e.g. R or £> configuration at the starred carbon atom). The in¬ vention covers all these diastereoisomers in pure form and also mixtures of diastereoisomers. Among compounds of particular interest are the com- pounds of formula I in which n (in formula II) is 3 or 4 and R 1 and R2 represent methyl, ethyl or n-propyl groups. Most preferred are the compounds in which n is 3 or 4 and R 1 and R2 represents ethyl groups. The compounds are formulated in pharmaceutical compo- sitions which are suitable for topical treatment, and in which the active ingredient comprises from 0.01 pp to 10 ppm. The formulations include liquid or semi-liquid prepa¬ rations such as liniments, lotions, applicants, oil-in- water or water-in-oil emulsions such a creams, ointments or pastes. In addition to the pharmaceutical carrier the formu¬ lations may include one or more additional ingredients such as diluents, buffers, flavouring agents, binders, surface active agents, thickeners, lubricants, preservatives, e.g. methyl hydroxybenzoate (including anti-oxidants), emulsify¬ ing agents and the like. The compositions may further contain other therapeu- tically active compounds usually applied in the treatment of skin ageing. The present invention further concerns a method for prevention of skin ageing or for treating patients already suffering from skin ageing, said method consisting of ad¬ ministering to a patient in need of treatment an effective amount of one or more compounds of formula I, alone or in combination with one or more other therapeutically active compounds usually applied in the treatment of skin ageing. The treatment with the present compounds and/or with fur¬ ther therapeutically active compounds may be simultaneous or with intervals. Example 1 Cream 1(S),3(R)-Dihydroxy-20(R)-(4'-hydroxy- -4*-methyl-1'-pentyloxy)-9,10- -seco-pregna-5(Z),7(E),10(19)-triene (active substance) 5 mg Cetomacrogol 1000 30 g Cetostearyl alcohol 60 g Chloroallylhexaminium chloride 0.5 g Propylenglycol 30 g Disodium hydrogenphosphate 2 g Sodium dihydrogenphosphate 0.1 g Liquid paraffin 50 g White petrolatum 170 g Purified water up to 1000 g Melt cetomacrogol 1000, cetostearyl alcohol, liquid paraffin and white petrolatum at 75°C. Dissolve propylen¬ glycol in water at 75°C and mix the solution with the fatty phase. Homogenize the emulsion and cool to 30°C. Mill the active compound to particle size below 5μm and suspend in an aqueous solution of disodium hydrogenphosphate, sodium dihydrogenphosphate and chloroallylhexaminium chloride. Add the suspension to the emulsion and fill the cream in tubes. Example 2 Ointment 1(S),3(R)-Dihydroxy-20(R)-(4'-hydroxy- -4'-ethyl-1'-hexyloxy)-9,10-seco- -pregna-5(Z),7(E),10(19)-triene (active substance) 1 mg Disodium hydrogen phosphate 0.5 g Polyoxyethylene(2)stearyl alcohol 60 g Propylene glycol 150 g Purified water 50 g White petrolatum 740 g Dissolve disodiumhydrogenphosphate and the active substance in a mixture of propylene glycol and water. Melt the white petrolatum and add the propylene glycol solution. Homogenize and cool the ointment during agitation. Fill the ointment into tubes. Example 3 Lotion 1(S),3(R)-Dihydroxy-20(R)-(5'-hydroxy- -5'-ethyl-1'-heptyloxy)-9,10-seco- -pregna-5(Z),7(E),10(19)-triene (active substance) Absolute alcohol Hydroxypropylcellulose Menthol Sodium citrate Propylenglycol Purified water up to Dissolve hydroxypropylcellulose, sodium citrate and 6 propylenglycol in water. Mix with a solution of the active substance and menthol in absolute alcohol. Fill the lotion in polyethylen plastic bottles. Example 4 Cream 1(S),3(R)-Dihydroxy-20(R)-(5 ' -hydroxy- -5'-methyl-1 '-hexyloxy)-9, 10- -seco-pregna-5(Z),7(E),10(19)-triene (active substance) 5 mg Cetomacrogol 1000 30 g Cetostearyl alcohol 60 g Chloroallylhexaminium chloride 0.5 g Propylenglycol 30 g Disodium hydrogenphosphate 2 g Sodium dihydrogenphosphate 0.1 g Liquid paraffin 50 g White petrolatum 170 g Purified water up to 1000 g Melt cetomacrogol 1000, cetostearyl alcohol, liquid paraffin and white petrolatum at 75°C. Dissolve propylen¬ glycol in water at 75°C and mix the solution with the fatty phase. Homogenize the emulsion and cool to 30°C. Mill the active compound to particle size below 5μm and suspend in an aqueous solution of disodium hydrogenphosphate, sodium dihydrogenphosphate and chloroallylhexaminium chloride. Add the suspension to the emulsion and fill the cream in tubes. Example 5 Effects of l(S),3(R)-Dihydroxy-20(R)-(4'-hydroxy-4'-ethyl- 1 '-hexyloxy)-9,10-seco-pregna-5(Z),7(E), 10(19)-triene (KH 1060) on epidermal thickness in rats The vitamin D analogue KH 1060 was formulated in a petrolatum ointment (containing 10% propylene glycol) at 5 μg/g ointment. The ointment was applied to the back of 5 Spraque-Dawley rats, 0.5 g per kg body weight, once daily for 4 weeks. Two other groups of 5 rats similarly received treatment with placebo ointment or ointment containing 1,25-dihydroxycholecalciferol (1,25(OH) 2 D 3 , 20 μg/g oint- ment). The administered dosage was thus 2.5 μg/kg body weight/day for KH 1060 and 10 μg/kg body weight/day for l,25(OH) 2 D 3 . At the end of treatment all animals were sacrificed by exsanguination and skin samples were removed for histo- pathological examination. The tissue was embedded in paraf¬ fin, sections of 4-5 mm were prepared and stained with hematoxylin and eosin. Microphotographs were taken at 100 x magnification. Fig 1. shows a section from the skin of rats treated with placebo ointment. A thin layer of epidermis is clearly visible at the left side of the section. Fig. 2 shows a section from the skin of rats treated with 1,25(0H) 2 D 3 ointment at 10 μg/kg/day. The thickness of the epidermal layer is similar to that seen in the rats treated with placebo ointment. Fig. 3 shows a section from the skin of rats treated with KH 1060 ointment at 2.5 μg/kg/day. A very striking thickening of the epidermal layer is seen (approx. 3 times the thickness of the skin from placebo treated rats). These changes were observed in all 5 rats treatment with KH 1060 ointment. No changes indicative of inflammatory processes were seen in the underlying dermal layers.

Claims: WHAT WE CLAIM IS : 1. The use of a compound selected from the group consist¬ ing of 20(R)-22-oxa-vitamin D analogues of the formula I in which formula R stands for an alkyl group containing from 4 to 12 carbon atoms optionally substituted with a hydroxy group, as described in international patent application No. PCT/DK90/00036, international filing date 13th February, 1990, International Publication No. WO 90/09991, in the manufacture of a medicament for the treatment of skin ageing. 2. The use according to claim 1, in which R in the active component is a group of formula II where n is an integer from 1 to 7; R 1 and R2, which may be the same or different, stand for hydrogen, lower alkyl. lower cycloalkyl, or, taken together with the carbon atom (starred in formula II) bearing the group X, R 1 and R2 can form a C 3 -C„ carbocyclic ring; X stands for hydrogen or hydroxy. 3. The use according to claim 2, in which n is 3 or 4 and R 1 and R2 represent methyl, ethyl or n-propyl groups. 4. The use according to claim 2, in which n is 3 or 4 and 1 7 R and R represent ethyl groups. 5. The use according to claim 1, in which the active com¬ ponent is l(S),3(R)-dihydroxy-20(R)-(5'-hydroxy-5'-methyl- -1'-hexyloxy)-9,10-seco-pregna-5(Z),7(E),10(19)-triene. 6. The use according to claim 1, in which the active com¬ ponent is l(S),3(R)-dihydroxy-20(R)-(4'-hydroxy-4'-ethyl- -1'-hexyloxy)-9,10-seco-pregna-5(Z),7(E),10(19)-triene 7. A topical medicament according to any one of claims 1 to 6, containing the active component in an amount of from 0.01 ppm to 10 ppm of the medicament. 8. The use of a compound, said compound as defined in any of the claims 1 to 6, for the treatment of skin ageing. 9. The use according to claim 8 of l(S),3(R)-dihydroxy- -20(R)-(5'-hydroxy-5'-methyl-1'-hexylox )-9,10-seco- -pregna-5(Z),7(E),10(19)-triene. 10. The use according to claim 8 of l(S),3(R)-dihydroxy- -20(R)-(4'-hydroxy-4'-ethyl-1'-hexyloxy)-9,10-seco-pregna- -5(Z),7(E),10(19)-triene

Inventors: BINDERUP LISE, BINDERUP, LISE
Applicants: LEO PHARM PROD LTD, LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOEVENS KEMIS
Application year: 1991
Main classification: A61K31
IPC codes: A61K8, A61K31, A61P17, A61Q19, C07C401, C07J5